Extended-release oxcarbazepine 2400 mg	Control	Seizure median percent improvement in North America	1637	1846	both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster
Extended-release oxcarbazepine 1200 mg	Control	Adverse effects 	24473	24651	he overall incidence of adverse events (Table 2) was similar in the placebo (55.4%) and SPN-804 1200-mg groups (56.6%) and was lower than in patients assigned to 2400 mg (69.1%).
Extended-release oxcarbazepine 1200 mg	Control	Seizure median percent improvement in North America	23215	23460	both SPN-804 dosage groups were significantly superior to placebo in median percent seizure reduction – placebo, −13.3%; 1200 mg, −34.5% (P = 0.02); 2400 mg, −52.7% (P = 0.006) among patients (n = 106) participating at North American study sites
Extended-release oxcarbazepine 1200 mg	Control	Seizure median percent improvement in North America	1637	1805	both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006)
Extended-release oxcarbazepine 1200 mg	Control	Overall seizure median percent reduction	1197	1349	Median percent reduction was -28.7% for placebo, −38.2% (P = 0.08 vs placebo) for once-daily SPN-804 1200 mg, and −42.9% (P = 0.003) for SPN-804 2400 mg
Extended-release oxcarbazepine 2400 mg	Control	Seizure median percent improvement in North America	23215	23460	both SPN-804 dosage groups were significantly superior to placebo in median percent seizure reduction – placebo, −13.3%; 1200 mg, −34.5% (P = 0.02); 2400 mg, −52.7% (P = 0.006) among patients (n = 106) participating at North American study sites
Extended-release oxcarbazepine 2400 mg	Control	Overall seizure median percent improvement 	1539	1847	When data were analyzed separately for study site clusters, a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster.
Extended-release oxcarbazepine 2400 mg	Control	Adverse effects 	24472	24650	The overall incidence of adverse events (Table 2) was similar in the placebo (55.4%) and SPN-804 1200-mg groups (56.6%) and was lower than in patients assigned to 2400 mg (69.1%)
Extended-release oxcarbazepine 2400 mg	Control	Overall seizure median percent improvement 	1197	1349	Median percent reduction was -28.7% for placebo, −38.2% (P = 0.08 vs placebo) for once-daily SPN-804 1200 mg, and −42.9% (P = 0.003) for SPN-804 2400 mg
